Fedro A Peccatori is an expert in Oncology at IRCCS Ospedale San Raffaele (Italy). As of October 2026, ScienceLeadR ranks Fedro A Peccatori in the top 1% of experts worldwide for Breast Neoplasms and Breast Diseases. Fedro A Peccatori has authored 399 publications, the most recent in 2026, and is an investigator in 4 clinical trials. SLR score: 1,353 (community average: 125). How the SLR is computed.

LeadR Profile

Fedro A Peccatori IRCCS Ospedale San Raffaele Italy
1 353 ScienceLeadR Reputation 1353
Network Map

Oncology

Subspecialties: Gynecology - Obstetrics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026

Source: PubMed

European Institute of Oncology

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 399

Citations

Citations: 17 222 1st author: 24 Last author: 85 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Legal Frameworks, Institutional Barriers and Unmet Needs of Young University Students With Cancer in Italy: A Call to Action.
PMID 42921979 — neoplasms, universities
Cancer Med20260
Digital solutions for tackling mental health in cancer patients and their families: The ALTHEA project.
PMID 42842547 — neoplasms, solutions, therapeutics, mental health
PLOS Digit Health20260
Surgical Management of Early-Onset Breast Cancer Among Young BRCA1 and BRCA2 Carriers.
PMID 42646839 — research design, mastectomy, genetic testing, breast neoplasms, neoplasms, cohort studies, clinical medicine, odds ratio, breast, diagnosis, therapeutics, genes, brca2, genes, brca1
JAMA Netw Open20260
Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer.
PMID 42580099 — breast neoplasms, neoplasms, drug therapy, chemotherapy, adjuvant, breast, anthracyclines, genes, brca1, chemotherapy
Eur J Cancer20260
Rate and risk factors of venous thromboembolism during neoadjuvant chemotherapy for advanced ovarian cancer: a retrospective analysis from a referral center.
PMID 42546374 — thromboembolism, ovary, neoplasms, drug therapy, ovarian neoplasms, risk factors, venous thromboembolism, chemotherapy
Int J Gynecol Cancer20260

Clinical Studies 4

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 3
Phase 2/Phase 3 1

By status:

Completed 2
Active not recruiting 1
Recruiting 1

By type:

Interventional 2
Observational 2

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 4

Main Topics

Cohort/Consortium Investigators 1

LeadR Networks

Main global connection map